Lilly signs licensing deal for early-stage diabetes therapy

Eli Lilly has inked a licensing deal with Taisho Pharmaceutical for a Phase I drug for type 2 diabetes. Lilly gained marketing rights for the drug outside of China and Japan. Financial details were not disclosed.

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.